Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 16, 2026, titled "Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) and approval letter from the USFDA following a Pre-Approval Inspection (PAI) at its SEZ oncology injectable manufacturing site in SEZ1, Ahmedabad. The inspection was conducted from 4th to 13th November, 2025. The approval specifically covers a new isolator injectable line at the facility. This disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Positive for shareholders as USFDA approval validates the company's manufacturing capabilities for oncology injectables, enabling the company to proceed with or expand its US market exports in this therapeutic segment.